FI107921B - Menetelmä terapeuttisesti käyttökelpoisten asyyliyhdisteiden valmistamiseksi - Google Patents
Menetelmä terapeuttisesti käyttökelpoisten asyyliyhdisteiden valmistamiseksi Download PDFInfo
- Publication number
- FI107921B FI107921B FI910747A FI910747A FI107921B FI 107921 B FI107921 B FI 107921B FI 910747 A FI910747 A FI 910747A FI 910747 A FI910747 A FI 910747A FI 107921 B FI107921 B FI 107921B
- Authority
- FI
- Finland
- Prior art keywords
- methyl
- biphenyl
- tetrazol
- ylmethyl
- amine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Magnetic Record Carriers (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cephalosporin Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Pyrrole Compounds (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI980787A FI980787A0 (fi) | 1990-02-19 | 1998-04-06 | Asyyliyhdisteet |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH51890 | 1990-02-19 | ||
CH51890 | 1990-02-19 | ||
CH223490 | 1990-07-05 | ||
CH223490 | 1990-07-05 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI910747A0 FI910747A0 (fi) | 1991-02-15 |
FI910747A FI910747A (fi) | 1991-08-20 |
FI107921B true FI107921B (fi) | 2001-10-31 |
Family
ID=25684817
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI910747A FI107921B (fi) | 1990-02-19 | 1991-02-15 | Menetelmä terapeuttisesti käyttökelpoisten asyyliyhdisteiden valmistamiseksi |
FI980787A FI980787A0 (fi) | 1990-02-19 | 1998-04-06 | Asyyliyhdisteet |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI980787A FI980787A0 (fi) | 1990-02-19 | 1998-04-06 | Asyyliyhdisteet |
Country Status (26)
Country | Link |
---|---|
US (2) | US5399578A (fr) |
EP (1) | EP0443983B1 (fr) |
JP (1) | JP2749458B2 (fr) |
KR (1) | KR0171409B1 (fr) |
AT (1) | ATE134624T1 (fr) |
AU (1) | AU644844B2 (fr) |
CA (2) | CA2232775C (fr) |
CY (2) | CY1978A (fr) |
DE (4) | DE19675036I2 (fr) |
DK (1) | DK0443983T3 (fr) |
ES (1) | ES2084801T3 (fr) |
FI (2) | FI107921B (fr) |
GR (1) | GR3019155T3 (fr) |
HK (1) | HK219996A (fr) |
HU (2) | HU219343B (fr) |
IE (1) | IE71155B1 (fr) |
IL (1) | IL97219A (fr) |
LU (4) | LU90100I2 (fr) |
LV (1) | LV5773B4 (fr) |
NL (3) | NL970001I2 (fr) |
NO (5) | NO304023B1 (fr) |
NZ (1) | NZ237126A (fr) |
PH (1) | PH30484A (fr) |
PT (1) | PT96799B (fr) |
SA (1) | SA93140130A (fr) |
UY (1) | UY23835A1 (fr) |
Families Citing this family (281)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU657498B2 (en) * | 1990-12-14 | 1995-03-16 | Novartis Ag | Biphenylyl compounds |
DE59208448D1 (de) * | 1991-08-15 | 1997-06-12 | Ciba Geigy Ag | N-Acyl-N-Heterocyclyl- oder Naphthylalkyl-Aminosäuren als Angiotensin II Antagonisten |
US5260325A (en) * | 1991-08-19 | 1993-11-09 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking tertiary amides |
US5252753A (en) * | 1991-11-01 | 1993-10-12 | Ortho Pharmaceutical Corporation | Process for the preparation of certain substituted biphenyl tetrazoles and compounds thereof |
DE69230721T2 (de) * | 1991-12-27 | 2000-08-31 | Kyowa Hakko Kogyo Kk | Tricyclische Verbindungen als Angiotensin-II-Antagonisten |
US5378701A (en) * | 1991-12-27 | 1995-01-03 | Kyowa Hakko Kogyo | Tricyclic compounds |
IL104755A0 (en) * | 1992-02-17 | 1993-06-10 | Ciba Geigy Ag | Treatment of glaucoma |
US5378715A (en) * | 1992-02-24 | 1995-01-03 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
US5514696A (en) * | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
US5312820A (en) * | 1992-07-17 | 1994-05-17 | Merck & Co., Inc. | Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines |
US5420123A (en) * | 1992-12-21 | 1995-05-30 | Bristol-Myers Squibb Company | Dibenzodiazepine endothelin antagonists |
US5256658A (en) * | 1993-01-15 | 1993-10-26 | Ortho Pharmaceutical Corporation | Angiotensin II inhibitors |
FR2711367B1 (fr) * | 1993-10-19 | 1995-12-01 | Roussel Uclaf | Nouveau procédé de préparation de dérivés soufrés de l'imidazole et les nouveaux intermédiaires obtenus. |
US5965732A (en) * | 1993-08-30 | 1999-10-12 | Bristol-Myers Squibb Co. | Sulfonamide endothelin antagonists |
HUT76542A (en) * | 1994-03-17 | 1997-09-29 | Ciba Geigy Ag | Use of valsartan for the preparation of pharmaceutical composition serving for the treatment of diabetic nephropathy |
JPH0853424A (ja) * | 1994-08-11 | 1996-02-27 | Kureha Chem Ind Co Ltd | ベンズイミダゾールスルホン酸アミド誘導体 |
US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
US5780473A (en) * | 1995-02-06 | 1998-07-14 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
US6071931A (en) * | 1995-10-06 | 2000-06-06 | Novartis Ag | AT1 -receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys |
JPH09124620A (ja) * | 1995-10-11 | 1997-05-13 | Bristol Myers Squibb Co | 置換ビフェニルスルホンアミドエンドセリン拮抗剤 |
AU1600297A (en) * | 1996-02-15 | 1997-09-02 | Novartis Ag | Aryl derivatives |
US5856507A (en) * | 1997-01-21 | 1999-01-05 | Bristol-Myers Squibb Co. | Methods for the preparation of biphenyl isoxazole sulfonamides |
HUP0002351A3 (en) | 1996-02-20 | 2001-10-29 | Bristol Myers Squibb Co | Methods for the preparation of biphenyl isoxazole sulfonamides, intermediates and process for preparing them |
ES2189940T3 (es) | 1996-02-29 | 2003-07-16 | Novartis Ag | Antagonista de receptor at1 para la estimulacion de la apoptosis. |
US5939446A (en) * | 1996-04-09 | 1999-08-17 | Bristol-Myers Squibb Co. | Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists |
KR980002035A (ko) * | 1996-06-17 | 1998-03-30 | 손경식 | 비페닐 유도체 및 그의 제조방법 및 그를 함유한 약제 조성물 |
GB9613470D0 (en) | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
WO1998033781A1 (fr) * | 1997-01-30 | 1998-08-06 | Bristol-Myers Squibb Company | Procede pour prevenir ou traiter l'hypertension due a une baisse de secretion de la renine, par l'administration d'un antagoniste de l'endotheline |
US5945441A (en) | 1997-06-04 | 1999-08-31 | Gpi Nil Holdings, Inc. | Pyrrolidine carboxylate hair revitalizing agents |
US6271244B1 (en) | 1998-06-03 | 2001-08-07 | Gpi Nil Holdings, Inc. | N-linked urea or carbamate of heterocyclic thioester hair growth compositions and uses |
US6187796B1 (en) | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Sulfone hair growth compositions and uses |
US20010049381A1 (en) | 1997-06-04 | 2001-12-06 | Gpl Nil Holdings, Inc., | Pyrrolidine derivative hair growth compositions and uses |
US6187784B1 (en) | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Pipecolic acid derivative hair growth compositions and uses |
US6274602B1 (en) | 1998-06-03 | 2001-08-14 | Gpi Nil Holdings, Inc. | Heterocyclic thioester and ketone hair growth compositions and uses |
WO1999062490A1 (fr) * | 1998-06-03 | 1999-12-09 | Gpi Nil Holdings, Inc. | Compositions pour la croissance des cheveux a base de petites molecules de sulfonamides et utilisation de ces compositions |
US6331537B1 (en) | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
US6172087B1 (en) | 1998-06-03 | 2001-01-09 | Gpi Nil Holding, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
WO1999062880A1 (fr) | 1998-06-03 | 1999-12-09 | Gpi Nil Holdings, Inc. | Sulfonamides a liaison n d'acides carboxyliques n-heterocycliques ou d'isosteres d'acide carboxylique |
US6429215B1 (en) | 1998-06-03 | 2002-08-06 | Gpi Nil Holdings, Inc. | N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses |
US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
CA2336714A1 (fr) * | 1998-07-06 | 2000-01-13 | Bristol-Myers Squibb Company | Biphenyl sulfonamides en tant que doubles antagonistes de recepteurs d'angiotensine et d'endotheline |
US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
KR100550167B1 (ko) * | 1998-07-10 | 2006-02-08 | 노파르티스 아게 | 발사르탄 및 칼슘 채널 차단제의 항고혈압 병용 제제 |
NZ587909A (en) * | 1998-12-23 | 2012-05-25 | Novartis Ag | Process of making a compressed tablets containing valsartan and microcrystalline cellulose |
EP1013273A1 (fr) * | 1998-12-23 | 2000-06-28 | Novartis AG | Utilisation des antagonistes du recepteur AT-1 ou des modulateurs du recepteur AT-2 pour le traitement de maladies asocciées à une augmentation de recepteurs AT-1 ou AT-2 |
US6465502B1 (en) * | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
CN101011390A (zh) * | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
PE20001456A1 (es) | 1999-02-02 | 2001-01-28 | Smithkline Beecham Corp | Compuestos calcioliticos |
WO2000056685A1 (fr) | 1999-03-19 | 2000-09-28 | Bristol-Myers Squibb Company | Procedes pour la preparation de diphenylisoxazolesulfonamides |
US6395728B2 (en) | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
JP4374102B2 (ja) * | 1999-09-24 | 2009-12-02 | 住友化学株式会社 | N,n−ジイソプロピルエチルアミンの分離方法 |
US6417189B1 (en) | 1999-11-12 | 2002-07-09 | Gpi Nil Holdings, Inc. | AZA compounds, pharmaceutical compositions and methods of use |
US7253169B2 (en) | 1999-11-12 | 2007-08-07 | Gliamed, Inc. | Aza compounds, pharmaceutical compositions and methods of use |
EP1237888B1 (fr) * | 1999-12-15 | 2006-09-13 | Bristol-Myers Squibb Company | Biphenyl sulfonamides utilises comme doubles antagonistes des recepteurs de l'angiotensine et de l'endotheline |
ATE319712T1 (de) | 1999-12-21 | 2006-03-15 | Mgi Gp Inc | Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung |
US20020132839A1 (en) * | 2000-06-22 | 2002-09-19 | Ganter Sabina Maria | Tablet formulations comprising valsartan |
WO2001097805A2 (fr) | 2000-06-22 | 2001-12-27 | Novartis Ag | Compositions pharmaceutiques |
MY136446A (en) * | 2000-07-19 | 2008-10-31 | Novartis Ag | New salts of valsartan |
US20060089389A1 (en) * | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
AR033390A1 (es) | 2000-08-22 | 2003-12-17 | Novartis Ag | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes |
US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
DE10059418A1 (de) * | 2000-11-30 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
US7531576B2 (en) * | 2000-12-26 | 2009-05-12 | Pola Chemical Industries, Inc. | Biphenyl derivatives |
SK288003B6 (sk) * | 2001-02-24 | 2012-10-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthin derivatives, method for the preparation thereof, pharmaceutical composition containing thereof and their use |
CN1589154A (zh) * | 2001-08-28 | 2005-03-02 | 三共株式会社 | 含有血管紧张肽ii受体拮抗剂的药用组合物 |
US7468390B2 (en) | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
US6869970B2 (en) * | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
EP2266590A3 (fr) | 2002-02-22 | 2011-04-20 | Shire LLC | Système d'administration de substances actives et méthodes de protection et d'administration de substances actives |
AU2003223637A1 (en) * | 2002-04-15 | 2003-11-03 | Dr. Reddy's Laboratories Limited | Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan) |
US20040072886A1 (en) * | 2002-04-15 | 2004-04-15 | Dr. Reddy's Laboratories Limited | Novel crystalline forms of (S)-N- (1-Carboxy-2-methyl-prop-1-yl) -N-pentanoyl-N- [2' -(1H-tetrazol-5-yl)- biphenyl-4-yl methyl] amine (Valsartan) |
EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
AP2005003232A0 (en) | 2002-08-19 | 2005-03-31 | Pfizer Prod Inc | Combination therapy for hyperproliferative diseases. |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
GB0222056D0 (en) * | 2002-09-23 | 2002-10-30 | Novartis Ag | Process for the manufacture of organic compounds |
AU2003241836A1 (en) | 2002-10-03 | 2004-04-23 | Ono Pharmaceutical Co., Ltd. | Lpa receptor antagonists |
DE10335027A1 (de) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
EP1950204A1 (fr) | 2003-03-17 | 2008-07-30 | Teva Pharmaceutical Industries Ltd. | Forme amorphe de valsartan |
US7199144B2 (en) | 2003-04-21 | 2007-04-03 | Teva Pharmaceuticals Industries, Ltd. | Process for the preparation of valsartan and intermediates thereof |
CA2519490A1 (fr) * | 2003-03-17 | 2004-09-30 | Teva Pharmaceutical Industries Ltd | Formes polymorphes de valsartan |
US20050165075A1 (en) * | 2003-03-31 | 2005-07-28 | Hetero Drugs Limited | Novel amorphous form of valsartan |
US7010633B2 (en) * | 2003-04-10 | 2006-03-07 | International Business Machines Corporation | Apparatus, system and method for controlling access to facilities based on usage classes |
WO2004094391A2 (fr) * | 2003-04-21 | 2004-11-04 | Teva Pharmaceutical Industries Ltd. | Procede de preparation du valsartan et de ses intermediaires |
US7378531B2 (en) | 2003-04-21 | 2008-05-27 | Teva Pharmaceutical Industries Ltd | Process for the preparation of valsartan |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
CZ298685B6 (cs) * | 2003-05-15 | 2007-12-19 | Zentiva, A.S. | Zpusob výroby N-(1-oxopentyl)-N-[[2´-(1H-tetrazol-5-yl)[1,1´-bifenyl]-4-yl]methyl]-L-valinu (valsartanu) |
UA82698C2 (uk) * | 2003-05-30 | 2008-05-12 | Ранбакси Лабораториз Лимитед | Заміщені похідні піролу та їх використання в якості інгібіторів hmg-co |
US7361770B2 (en) * | 2003-06-16 | 2008-04-22 | Hetero Drugs Limited | Process for preparation of valsartan |
GB0316546D0 (en) | 2003-07-15 | 2003-08-20 | Novartis Ag | Process for the manufacture of organic compounds |
US20050037063A1 (en) * | 2003-07-21 | 2005-02-17 | Bolton Anthony E. | Combined therapies |
DE602004029373D1 (de) * | 2003-08-27 | 2010-11-11 | Zentiva Ks | Verfahren zur entfernung der triphenylmethanschutzgruppe |
AU2004270162B2 (en) * | 2003-08-28 | 2010-05-13 | Nicox S.A. | Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use |
JP4537678B2 (ja) * | 2003-09-04 | 2010-09-01 | 住友化学株式会社 | 2’−(1h−テトラゾール−5−イル)ビフェニル−4−カルボアルデヒド結晶およびその製造方法 |
CA2541867C (fr) * | 2003-10-10 | 2012-06-12 | Solvay Pharmaceuticals Gmbh | Composition pharmaceutique comprenant un agoniste des recepteurs de l'imidazoline i1 selectif et un bloqueur des recepteurs de l'angiotensine ii |
AU2004293013B2 (en) | 2003-11-19 | 2011-04-28 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
WO2005049587A1 (fr) * | 2003-11-21 | 2005-06-02 | Ranbaxy Laboratories Limited | Procede de preparation de tetrazole de biphenyle |
ITMI20032267A1 (it) * | 2003-11-21 | 2005-05-22 | Dinamite Dipharma S P A In Forma A Bbreviata Diph | Procdimento per la preparzione di valsartan e suoi intermedi |
HRP20030965A2 (en) * | 2003-11-24 | 2005-08-31 | Belupo - Lijekovi I Kozmetika D.D. | Process for production of (s)-n-pentanoyl-n-[[2'-( |
GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
GB0402262D0 (en) | 2004-02-02 | 2004-03-10 | Novartis Ag | Process for the manufacture of organic compounds |
US7501426B2 (en) * | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
TW200605867A (en) | 2004-03-17 | 2006-02-16 | Novartis Ag | Use of organic compounds |
ES2251292B1 (es) * | 2004-04-20 | 2007-07-01 | Inke, S.A. | Procedimiento para la obtencion de un compuesto farmaceuticamente activo y de sus intermedios de sintesis. |
JP4793692B2 (ja) * | 2004-04-26 | 2011-10-12 | 小野薬品工業株式会社 | 新規なblt2介在性疾患、blt2結合剤および化合物 |
CZ298471B6 (cs) * | 2004-05-19 | 2007-10-10 | Zentiva, A.S. | Soli benzylesteru N-[(2´-(1H-tetrazol-5-yl)bifenyl-4-yl)methyl]-(L)-valinu a jejich použití pro výrobu valsartanu |
EP1764075A4 (fr) * | 2004-07-02 | 2010-08-04 | Sankyo Co | Inhibiteur de la production de facteur tissulaire |
US20080085914A1 (en) | 2004-10-08 | 2008-04-10 | David Louis Feldman | Use Of Organic Compounds |
CA2585623C (fr) | 2004-10-27 | 2012-06-05 | Daiichi Sankyo Company Limited | Derives de benzene substitue en position ortho |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
WO2006067216A2 (fr) | 2004-12-22 | 2006-06-29 | Enantia, S. L. | Composes intermediaires pour la preparation d'un antagoniste du recepteur de l'angiotensine ii |
SI2033629T1 (sl) * | 2004-12-24 | 2013-01-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Trden farmacevtski sestavek, ki obsega valsartan |
US7659406B2 (en) * | 2005-01-03 | 2010-02-09 | Dr. Reddy's Laboratories Limited | Process for preparing valsartan |
JP2007527924A (ja) * | 2005-01-11 | 2007-10-04 | テバ ファーマシューティカル インダストリーズ リミティド | 非晶質バルサルタンの製造方法 |
US20060281801A1 (en) * | 2005-04-19 | 2006-12-14 | Ashok Kumar | Process for the preparation of valsartan and its intermediates |
EP1896433A4 (fr) * | 2005-05-25 | 2010-06-02 | Ipca Lab Ltd | Nouvelles formes cristallines de (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine |
US20070117987A1 (en) * | 2005-07-05 | 2007-05-24 | Viviana Braude | Process for preparing valsartan |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
AT502219B1 (de) * | 2005-08-04 | 2007-04-15 | Sanochemia Pharmazeutika Ag | Verfahren zur reindarstellung von 5-substituierten tetrazolen |
EP1922069A2 (fr) * | 2005-08-08 | 2008-05-21 | Nitromed, Inc. | Composes antagonistes de l'angiotensine ii amplifiant l'oxyde nitrique, compositions et methodes d'utilisation associees |
KR20080039510A (ko) * | 2005-08-22 | 2008-05-07 | 알렘빅 리미티드 | 발사르탄 제조 방법 |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
WO2007057919A2 (fr) * | 2005-10-25 | 2007-05-24 | Alembic Limited | Procede ameliore pour la preparation de (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine |
WO2007052307A2 (fr) * | 2005-10-31 | 2007-05-10 | Lupin Limited | Formes posologiques solides orales stables de valsartan |
WO2007054896A1 (fr) * | 2005-11-08 | 2007-05-18 | Ranbaxy Laboratories Limited | Procede de preparation de sel hemicalcique d’acide (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoique |
AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
RU2459809C2 (ru) * | 2005-11-09 | 2012-08-27 | Новартис Аг | Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US20070141533A1 (en) * | 2005-12-20 | 2007-06-21 | Ford Christopher W | Polymeric dental implant assembly |
US20070166372A1 (en) * | 2006-01-19 | 2007-07-19 | Mai De Ltd. | Preparation of solid coprecipitates of amorphous valsartan |
WO2007088558A2 (fr) * | 2006-02-02 | 2007-08-09 | Alembic Limited | Procédé de purification du valsartan |
AR059838A1 (es) * | 2006-03-14 | 2008-04-30 | Ranbaxy Lab Ltd | Formulaciones para dosis estabilizantes de estatina |
EP1852108A1 (fr) * | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | Compositions d'inhibiteurs de la DPP IV |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
CN109503584A (zh) | 2006-05-04 | 2019-03-22 | 勃林格殷格翰国际有限公司 | 多晶型 |
US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
RS20080525A (en) | 2006-05-09 | 2009-09-08 | Pfizer Products Inc., | Cycloalkylamino acid derivatives and pharmaceutical compositions thereof |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
CZ300801B6 (cs) * | 2006-06-07 | 2009-08-12 | Helvetia Pharma A.S. | Kompozice s valsartanem v pevných lékových formách |
EP2043607A2 (fr) * | 2006-06-23 | 2009-04-08 | Usv Limited | Procédé de préparation de valsartan micronisé |
US20080004313A1 (en) * | 2006-06-28 | 2008-01-03 | Mai De Ltd. | Preparation of crystalline polymorphs of rimonabant hydrochloride |
US7880015B2 (en) * | 2006-07-03 | 2011-02-01 | Aurobindo Pharma Ltd. | Process for the preparation of angiotensin II antagonist |
AR063469A1 (es) * | 2006-07-14 | 2009-01-28 | Ranbaxy Lab Ltd | Formas polimorficas de ácido (3r,5r)-7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroximetilfenilamino)carbonil]-pirrol-1-il]-3, 5-dihidroxi-heptanoico, sal hemicalcio, metodos de preparacion de las mismas, una composicion farmaceutica que las comprende y su uso en el tratamiento de enfermedades |
JP5399902B2 (ja) | 2006-08-22 | 2014-01-29 | ランバクシー ラボラトリーズ リミテッド | マトリックスメタロプロテイナーゼ阻害剤 |
EP1908469A1 (fr) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Antagonistes du récepteur de l'angiotensine II pour traiter des désordres sistémiques des chats |
CN101663262B (zh) | 2006-12-01 | 2014-03-26 | 百时美施贵宝公司 | 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物 |
US20100217008A1 (en) * | 2006-12-14 | 2010-08-26 | Ratiopharm Gmbh | Process for the preparation of valsartan and intermediate products |
KR101580067B1 (ko) | 2007-01-12 | 2015-12-23 | 노파르티스 아게 | 5-바이페닐-4-아미노-2-메틸 펜탄산의 제조 방법 |
TW200838501A (en) * | 2007-02-02 | 2008-10-01 | Theravance Inc | Dual-acting antihypertensive agents |
CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
US20110027358A1 (en) * | 2007-03-29 | 2011-02-03 | Rajesh Kshirsagar | Valsartan tablet formulations |
EP2865670B1 (fr) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase |
TWI448284B (zh) | 2007-04-24 | 2014-08-11 | Theravance Inc | 雙效抗高血壓劑 |
WO2008135762A1 (fr) * | 2007-05-07 | 2008-11-13 | Cipla Limited | Procédé de préparation du valsartan |
US20080299218A1 (en) * | 2007-06-01 | 2008-12-04 | Protia, Llc | Deuterium-enriched valsartan |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
AU2008261102B2 (en) | 2007-06-04 | 2013-11-28 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
TWI406850B (zh) | 2007-06-05 | 2013-09-01 | Theravance Inc | 雙效苯并咪唑抗高血壓劑 |
EP1849777B1 (fr) * | 2007-06-07 | 2008-10-29 | Inke, S.A. | Procédé pour l'obtention d'un sel de valsartan utile pour l'obtention de valsartan |
EP2167477B1 (fr) * | 2007-06-27 | 2013-02-27 | Mylan Laboratories Limited | Procédé pour préparer du valsartan pur |
GB0715628D0 (en) * | 2007-08-10 | 2007-09-19 | Generics Uk Ltd | Solid valsartan composition |
WO2009024542A2 (fr) * | 2007-08-17 | 2009-02-26 | Boehringer Ingelheim International Gmbh | Utilisation de dérivés de la purine |
US7834041B2 (en) | 2007-09-07 | 2010-11-16 | Theravance, Inc. | Dual-acting antihypertensive agents |
DK2209786T3 (da) * | 2007-10-05 | 2013-06-03 | Verastem Inc | Pyrimidinsubstituerede purinderivater |
JP2011500577A (ja) | 2007-10-09 | 2011-01-06 | ノバルティス アーゲー | バルサルタンの医薬製剤 |
BRPI0820198A2 (pt) | 2007-11-12 | 2019-09-24 | Novartis Ag | composições farmacêuticas |
JP2011506459A (ja) | 2007-12-11 | 2011-03-03 | セラヴァンス, インコーポレーテッド | 抗高血圧剤としての二重作用性ベンゾイミダゾール誘導体およびその使用 |
WO2009084003A1 (fr) * | 2007-12-31 | 2009-07-09 | Lupin Limited | Compositions pharmaceutiques d'amlodipine et de valsartan |
US7943794B2 (en) * | 2008-02-13 | 2011-05-17 | Ranbaxy Laboratories Limited | Processes for the preparation of intermediates of valsartan |
US20090226515A1 (en) * | 2008-03-04 | 2009-09-10 | Pharma Pass Ii Llc | Statin compositions |
US20090226516A1 (en) * | 2008-03-04 | 2009-09-10 | Pharma Pass Ii Llc | Sartan compositions |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
EP2260018A2 (fr) * | 2008-04-07 | 2010-12-15 | Hetero Research Foundation | Procédé de préparation d'un intermédiaire de valsartan |
JP2011518884A (ja) | 2008-04-29 | 2011-06-30 | セラヴァンス, インコーポレーテッド | 二重活性抗高血圧剤 |
KR100995734B1 (ko) | 2008-05-28 | 2010-11-19 | 일동제약주식회사 | 발사르탄의 개선된 제조방법 |
PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
CA2930674A1 (fr) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles |
JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
WO2010011821A2 (fr) | 2008-07-24 | 2010-01-28 | Theravance, Inc. | Agents anti-hypertensifs à double action |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
BRPI0917675A2 (pt) * | 2008-08-15 | 2015-12-01 | Boehringer Ingelheim Int | compostos orgânicos para cura de ferida |
CN101362728B (zh) * | 2008-08-22 | 2011-07-20 | 北京赛科药业有限责任公司 | 一种缬沙坦的合成方法 |
MX2011002558A (es) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Terapia de combinacion para el tratamiento de diabetes y estados relacionados. |
CA2740075A1 (fr) * | 2008-10-10 | 2010-04-15 | Janssen Pharmaceutica Nv | Therapie d'association comprenant des inhibiteurs de recepteur d'angiotensine et antagonistes de recepteur de vasopressine |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
EP2194048A1 (fr) | 2008-12-02 | 2010-06-09 | Dirk Sartor | Esters de nitrate pour le traitement de maladies vasculaires et métaboliques |
KR101012135B1 (ko) | 2008-12-18 | 2011-02-07 | 주식회사 대희화학 | 발사르탄 메틸 에스테르의 제조방법 |
EA022310B1 (ru) | 2008-12-23 | 2015-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Солевые формы органического соединения |
US9387249B2 (en) | 2008-12-23 | 2016-07-12 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone |
CN101768128B (zh) * | 2009-01-05 | 2012-10-10 | 浙江华海药业股份有限公司 | 一种含10%以上异构体的缬沙坦的精制方法 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
CN101475540B (zh) * | 2009-01-22 | 2011-05-11 | 江苏德峰药业有限公司 | 一种缬沙坦的制备方法 |
US20120046364A1 (en) | 2009-02-10 | 2012-02-23 | Metabasis Therapeutics, Inc. | Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use |
US7956054B2 (en) | 2009-07-07 | 2011-06-07 | Theravance, Inc. | Dual-acting pyrazole antihypertensive agents |
WO2011011232A1 (fr) | 2009-07-22 | 2011-01-27 | Theravance, Inc. | Agents antihypertenseurs à double action à base d'oxazole |
EP2475428B1 (fr) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase |
EP2316821A1 (fr) * | 2009-10-27 | 2011-05-04 | Novartis AG | Procédé pour la fabrication de composés organiques |
MX364651B (es) | 2009-11-27 | 2019-05-03 | Boehringer Ingelheim Int Gmbh Star | Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente. |
JP2013517295A (ja) | 2010-01-19 | 2013-05-16 | セラヴァンス, インコーポレーテッド | 二重に作用するチオフェン、ピロール、チアゾールおよびフラン抗高血圧症薬 |
KR101152144B1 (ko) * | 2010-02-01 | 2012-06-15 | 경동제약 주식회사 | 발사르탄의 제조 방법 및 이에 사용되는 신규 중간체 |
EP2536396B1 (fr) | 2010-02-16 | 2016-08-10 | KRKA, D.D., Novo Mesto | Procédé pour la préparation de formes posologiques solides orales comprenant du valsartan |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
AU2011226074B2 (en) | 2010-03-10 | 2015-01-22 | Vivoryon Therapeutics N.V. | Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5) |
WO2011124655A1 (fr) * | 2010-04-07 | 2011-10-13 | Krka, D.D., Novo Mesto | Procédé amélioré pour préparer du valsartan |
CA2796710A1 (fr) | 2010-04-19 | 2011-10-27 | Cardiolynx Ag | Derives de valsartan portant des donneurs d'oxyde d'azote dans le traitement de maladies vasculaires et metaboliques |
WO2011131748A2 (fr) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Nouveaux inhibiteurs |
EP2566469B1 (fr) | 2010-05-05 | 2022-12-21 | Boehringer Ingelheim International GmbH | Thérapie combinée |
EA201991014A1 (ru) | 2010-06-24 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение диабета |
US8981109B2 (en) | 2010-07-02 | 2015-03-17 | Aurobindo Pharma Ltd | Process for the preparation of valsartan |
TR201005419A2 (tr) | 2010-07-05 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Valsartan içeren farmasötik bileşim. |
CA2806657A1 (fr) | 2010-08-03 | 2012-02-09 | Novartis Ag | Valsartan hautement cristallin |
CA2806780A1 (fr) | 2010-08-23 | 2012-03-01 | Novartis Ag | Procede de preparation d'intermediaires pour produire des inhibiteurs de l'endopeptidase neutre (epn) |
KR101864865B1 (ko) | 2010-08-24 | 2018-06-05 | 노파르티스 아게 | 항응고제 요법을 받고 있는 포유동물에서의 고혈압의 치료 및/또는 심부전의 예방 또는 치료 |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2012056294A1 (fr) | 2010-10-29 | 2012-05-03 | Jubilant Life Sciences Ltd. | Procédé amélioré de préparation de n-pentanoyl-n-[[2'-(1h-tétrazol-5-yl)[1,1'-biphényl]-4-yl]méthyl]-l-valine |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
EP2675792B1 (fr) * | 2011-02-17 | 2016-01-06 | Theravance Biopharma R&D IP, LLC | Dérivés aminobutyriques substitués utilisés en tant qu'inhibiteurs de néprilysine |
DK2686313T3 (en) | 2011-03-16 | 2016-05-02 | Probiodrug Ag | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
FR2977253B1 (fr) | 2011-06-30 | 2013-08-09 | Centre Nat Rech Scient | Reactif organostannique alcoxyle supporte, preparation et utilisation pour la synthese de tetrazoles en phase heterogene |
US8883800B2 (en) | 2011-07-15 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
US9522873B2 (en) | 2011-08-05 | 2016-12-20 | Dongguk University Industry-Academic Cooperation Foundation | Biphenyl derivative, pharmaceutically acceptable salt thereof, and methods for preventing or treating inflammatory diseases or autoimmune diseases |
EP2747757A1 (fr) | 2011-08-26 | 2014-07-02 | Wockhardt Limited | Procédés de traitement de troubles cardiovasculaires |
WO2013090196A1 (fr) | 2011-12-15 | 2013-06-20 | Takeda Pharmaceuticals U.S.A., Inc. | Combinaisons d'azilsartan et de chlorthalidone pour le traitement de patients hypertendus noires |
KR20140108652A (ko) | 2011-12-26 | 2014-09-12 | 노파르티스 아게 | 정제 및 건식-코팅된 작용제 |
WO2013098578A1 (fr) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Composition pharmaceutique d'hydrochlorothiazide de valsartan à libération immédiate |
WO2013098576A1 (fr) | 2011-12-31 | 2013-07-04 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Composition pharmaceutique de valsartan à libération immédiate |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
ES2656292T3 (es) | 2012-05-01 | 2018-02-26 | Translatum Medicus Inc. | Métodos de tratamiento y diagnóstico de enfermedades oculares que causan ceguera |
WO2013171167A1 (fr) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | Dérivé de xanthine en tant qu'inhibiteur de dpp-4 pour l'utilisation dans le traitement de troubles associés aux podocytes et/ou un syndrome néphrotique |
WO2013174767A1 (fr) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires |
SI2887961T1 (sl) | 2012-08-24 | 2021-08-31 | Novartis Ag | Zaviralci NEP za zdravljenje bolezni, značilnih po atrialni širitvi ali preoblikovanju |
WO2014118721A1 (fr) | 2013-01-30 | 2014-08-07 | Ranbaxy Laboratories Limited | Formes dosifiées solides orales pharmaceutiques comprenant du valsartan et du nébivolol |
US20160045497A1 (en) | 2013-03-12 | 2016-02-18 | Lg Life Sciences Ltd. | Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor |
JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
CA2905438A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonistes de la guanylate cyclase et leurs utilisations |
MX2015014666A (es) | 2013-04-17 | 2016-03-01 | Pfizer | Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares. |
JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法 |
SI3626270T1 (sl) | 2013-08-26 | 2024-03-29 | Novartis Ag | Zdravljenje srčno-žilnih bolezni |
WO2015030711A1 (fr) | 2013-08-26 | 2015-03-05 | Novartis Ag | Nouvelle utilisation |
WO2015056219A1 (fr) | 2013-10-18 | 2015-04-23 | Ranbaxy Laboratories Limited | Procédé de séchage et de micronisation simultanés de valsartan |
WO2015128453A1 (fr) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Utilisation médicale d'un inhibiteur de dpp-4 |
CN103923028B (zh) * | 2014-05-04 | 2017-05-24 | 青岛雪洁助剂有限公司 | 一种缬沙坦甲酯的制备方法 |
CN104072386A (zh) * | 2014-06-28 | 2014-10-01 | 浙江华海药业股份有限公司 | 一种缬沙坦中间体的改进方法 |
WO2016037552A1 (fr) * | 2014-09-09 | 2016-03-17 | 上海翰森生物医药科技有限公司 | Composé cristallin bloqueur de récepteur de l'angiotensine-inhibiteur d'endopeptidase neutre (arb-nepi), son procédé de préparation et son application |
WO2016055901A1 (fr) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Composés d'amide substitué |
JP6382736B2 (ja) * | 2015-02-02 | 2018-08-29 | 株式会社トクヤマ | バルサルタンの製造方法 |
FI3294283T3 (fi) | 2015-05-11 | 2023-05-24 | Novartis Ag | Sakubitriili-valsartaani-annostusohjelma sydämen vajaatoiminnan hoitamiseksi |
JP2018516267A (ja) | 2015-05-29 | 2018-06-21 | ノバルティス アーゲー | 代謝性疾患を治療するためのサクビトリルおよびバルサルタン |
US10689352B2 (en) | 2015-06-12 | 2020-06-23 | Teva Pharmaceuticals International Gmbh | Solid state forms of trisodium valsartan: sacubitril |
WO2017006254A1 (fr) | 2015-07-08 | 2017-01-12 | Novartis Ag | Combinaison de médicaments comprenant un antagoniste du récepteur de l'angiotensine ii, un inhibiteur d'endopeptidase neutre et un antagoniste du récepteur de minéralocorticoïdes |
LT3325013T (lt) | 2015-07-23 | 2020-11-10 | Bayer Pharma Aktiengesellschaft | Tirpios guanilatciklazės (sgc) stimuliatoriai/aktyvatoriai derinyje su nep inhibitoriumi ir (arba) angiotenzino aii antagonistu ir jų naudojimas |
EP3355880A1 (fr) | 2015-08-28 | 2018-08-08 | Novartis AG | Nouvelle utilisation |
WO2017134600A1 (fr) | 2016-02-03 | 2017-08-10 | Novartis Ag | Nouvelle utilisation d'une combinaison de sacubitril et de valsartan |
WO2017211979A1 (fr) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinaisons de linagliptine et de metformine |
WO2018002673A1 (fr) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Nouvelles formulations d'antagonistes du récepteur de l'angiotensine ii |
US10745363B2 (en) | 2016-09-02 | 2020-08-18 | Nanjing Noratech Pharmaceuticals Co., Ltd | Crystal forms of valsartan disodium salt |
CN107056720A (zh) * | 2016-12-30 | 2017-08-18 | 湖南千金湘江药业股份有限公司 | 一种缬沙坦的制备和纯化方法 |
EP3342400A1 (fr) | 2016-12-31 | 2018-07-04 | Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. | Composition pharmaceutique comprenant de la valsartane et du chlorthalidone |
WO2018153895A1 (fr) | 2017-02-22 | 2018-08-30 | Bayer Pharma Aktiengesellschaft | Agonistes partiels sélectifs du récepteur a1 de l'adénosine en combinaison avec un inhibiteur de l'endopeptidase neutre et/ou un antagoniste du récepteur de l'angiotensine ii |
EA202090205A1 (ru) | 2017-07-07 | 2020-06-02 | Бёрингер Ингельхайм Ветмедика Гмбх | Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов |
ES2881317T3 (es) | 2017-07-28 | 2021-11-29 | Synthon Bv | Composición farmacéutica que comprende sacubitrilo y valsartán |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
EP3498698A1 (fr) | 2017-12-15 | 2019-06-19 | Mankind Pharma Ltd | Formes solides de valsartan disodium et son procédé de préparation |
WO2019200181A1 (fr) | 2018-04-11 | 2019-10-17 | Ohio State Innovation Foundation | Procédés et compositions pour microparticules à libération prolongée pour l'administration de médicament oculaire |
US11081240B2 (en) | 2018-06-14 | 2021-08-03 | Astrazeneca Uk Limited | Methods for treatment of hypertension with an angiotensin II receptor blocker pharmaceutical composition |
US20210177803A1 (en) | 2018-08-23 | 2021-06-17 | Novartis Ag | New pharmaceutical use for the treatment of heart failure |
WO2020039394A1 (fr) | 2018-08-24 | 2020-02-27 | Novartis Ag | Nouvelles combinaisons de médicaments |
US10548838B1 (en) | 2018-12-14 | 2020-02-04 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
US11413275B1 (en) | 2018-12-14 | 2022-08-16 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
US10478422B1 (en) | 2018-12-14 | 2019-11-19 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
EP3911648A4 (fr) | 2019-01-18 | 2022-10-26 | Astrazeneca AB | Inhibiteurs de pcsk9 et leurs procédés d'utilisation |
US11446243B1 (en) | 2019-08-05 | 2022-09-20 | ECI Pharmaceuticals, LLC | Oral liquid compositions including valsartan |
EP3939967A1 (fr) | 2020-07-15 | 2022-01-19 | KRKA, d.d., Novo mesto | Procédé continu pour la préparation de (s)-méthyl n-((2'-cyano-[1,1'-biphényl]-4-yl)méthyl)-n-pentanoylvalinate dans un réacteur à écoulement |
KR20220012821A (ko) | 2020-07-23 | 2022-02-04 | 주식회사 종근당 | 이중 작용 복합 화합물의 결정형 및 이의 제조방법 |
US11655220B2 (en) | 2020-10-22 | 2023-05-23 | Hetero Labs Limited | Process for the preparation of angiotensin II receptor blockers |
CN113387805B (zh) * | 2021-07-21 | 2024-01-12 | 黑龙江立科新材料有限公司 | 基于烷基重氮盐取代反应的化合物的制备方法 |
WO2024019957A1 (fr) * | 2022-07-18 | 2024-01-25 | Celgene Corporation | Composés pour le traitement de maladies neurodégénératives |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB973975A (en) * | 1962-05-23 | 1964-11-04 | Painton & Co Ltd | Improvements in or relating to electric switches |
SE307365B (fr) * | 1966-05-28 | 1969-01-07 | Yoshitomi Pharmaceutical | |
SE447653B (sv) * | 1978-11-14 | 1986-12-01 | Eisai Co Ltd | Imidazolderivat samt farmaceutisk komposition innehallande sadant derivat |
JPS5671074A (en) * | 1979-11-12 | 1981-06-13 | Takeda Chem Ind Ltd | 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative |
US4333943A (en) * | 1980-04-24 | 1982-06-08 | Miles Laboratories, Inc. | Ethyl 3-(3-indolyl)-3-(5-tetrazolyl) propionate compounds used as anti-hypertensive agents |
JPS59128376A (ja) * | 1983-01-13 | 1984-07-24 | Tanabe Seiyaku Co Ltd | キナゾリノン誘導体 |
EP0142754A2 (fr) * | 1983-11-04 | 1985-05-29 | Ferrer Internacional, S.A. | Acides benzoiques substitués sur la position 2, ayant un groupe imidazolyl, procédé pour leur préparation et compositions pharmaceutiques les contenant |
US4551279A (en) * | 1984-01-09 | 1985-11-05 | G. D. Searle & Co. | Protease inhibitors |
US4578386A (en) * | 1984-02-10 | 1986-03-25 | Usv Pharmaceutical Corp. | 7,8-Dihydroimidazo[1,5-a]pyrazin-8-ones |
US4755518A (en) * | 1985-12-20 | 1988-07-05 | Warner-Lambert Company | Imidazolyl or tetrazolyl substituted benzoic acid derivatives and pharmaceutical compositions thereof |
US4748245A (en) * | 1986-03-20 | 1988-05-31 | Stauffer Chemical Company | Process for making phenylthiopyrimidines |
US4816463A (en) * | 1986-04-01 | 1989-03-28 | Warner-Lambert Company | Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity |
US4812462A (en) * | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
US5138069A (en) * | 1986-07-11 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking imidazoles |
ZA875052B (en) * | 1986-07-11 | 1989-03-29 | Du Pont | Angiotensin ii receptor blocking imidazoles |
CA1334092C (fr) * | 1986-07-11 | 1995-01-24 | David John Carini | Imidazoles bloquant les recepteurs de l'angiotensine ii |
US4820843A (en) * | 1987-05-22 | 1989-04-11 | E. I. Du Pont De Nemours And Company | Tetrazole intermediates to antihypertensive compounds |
US4874867A (en) * | 1987-05-22 | 1989-10-17 | E. I. Du Pont De Nemours And Company | Tetrazole intermediates to antihypertensive compounds |
US4870186A (en) * | 1987-05-22 | 1989-09-26 | E. I. Du Pont De Nemours And Company | Tetrazole intermediates to antihypertensive compounds |
US4921632A (en) * | 1987-08-26 | 1990-05-01 | Nec Corporation | Liquid crystal compounds and compositions |
US4880804A (en) * | 1988-01-07 | 1989-11-14 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking benzimidazoles |
US5189048A (en) * | 1988-01-07 | 1993-02-23 | E. I. Du Pont De Nemours And Company | Substituted 1,2,3 triazole angiotensin II antagonists |
CA1338238C (fr) * | 1988-01-07 | 1996-04-09 | David John Carini | Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens |
US5015651A (en) * | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
GB8827820D0 (en) * | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
US4916129A (en) * | 1989-01-19 | 1990-04-10 | E. I. Du Pont De Nemours And Company | Combination β-blocking/angiotensin II blocking antihypertensives |
DE3928177A1 (de) * | 1989-04-08 | 1991-02-28 | Thomae Gmbh Dr K | Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
CA2016710A1 (fr) * | 1989-05-15 | 1990-11-15 | Prasun K. Chakravarty | Benzimidazoles substitues comme antagonistes de l'antiotensine ii |
IE64514B1 (en) * | 1989-05-23 | 1995-08-09 | Zeneca Ltd | Azaindenes |
GB8911854D0 (en) * | 1989-05-23 | 1989-07-12 | Ici Plc | Heterocyclic compounds |
IL94390A (en) * | 1989-05-30 | 1996-03-31 | Merck & Co Inc | The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them |
US5064825A (en) * | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
EP0955294B1 (fr) * | 1989-06-14 | 2003-09-24 | Smithkline Beecham Corporation | Acides imidazoalcénoiques |
CA2018443A1 (fr) * | 1989-06-14 | 1990-12-14 | Joseph A. Finkelstein | Acides imidazolyl-alkenoiques |
WO1991000281A2 (fr) * | 1989-06-30 | 1991-01-10 | E.I. Du Pont De Nemours And Company | Imidazoles a substitution aryle a anneau fusionne |
WO1991000277A1 (fr) * | 1989-06-30 | 1991-01-10 | E.I. Du Pont De Nemours And Company | Imidazoles substitues |
US5164407A (en) * | 1989-07-03 | 1992-11-17 | Merck & Co., Inc. | Substituted imidazo-fused 5-membered ring heterocycles and their use as angiotensin ii antagonsists |
EP0409332A3 (en) * | 1989-07-19 | 1991-08-07 | Merck & Co. Inc. | Substituted triazoles as angiotensin ii antagonists |
DE69024556T2 (de) * | 1989-07-28 | 1996-10-17 | Merck & Co Inc | Substituierte Triazolinone, Triazolinthione und Triazolinimine als Angiotensin II-Antagonisten |
ATE113281T1 (de) * | 1989-08-02 | 1994-11-15 | Takeda Chemical Industries Ltd | Pyrazol-derivate, verfahren zu deren herstellung und anwendung. |
PL286445A1 (en) * | 1989-08-11 | 1991-04-22 | Ici Plc | Method of obtaining novel quinoline derivatives |
US5100897A (en) * | 1989-08-28 | 1992-03-31 | Merck & Co., Inc. | Substituted pyrimidinones as angiotensin ii antagonists |
IE70593B1 (en) * | 1989-09-29 | 1996-12-11 | Eisai Co Ltd | Biphenylmethane derivative the use of it and pharmacological compositions containing same |
US5298518A (en) * | 1989-09-29 | 1994-03-29 | Eisai Co., Ltd. | Biphenylmethane derivative and pharmacological use |
IL95975A (en) * | 1989-10-24 | 1997-06-10 | Takeda Chemical Industries Ltd | N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them |
CA2027937A1 (fr) * | 1989-10-25 | 1991-04-26 | Richard M. Keenan | 5-¬(tetrazolyle)alcenyle|imidazoles substitues |
IL96019A0 (en) * | 1989-10-31 | 1991-07-18 | Fujisawa Pharmaceutical Co | Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same |
CA2028925A1 (fr) * | 1989-11-06 | 1991-05-07 | Gerald R. Girard | Derives substitues de la n-(imidazolyl)alkylalanine |
PT95899A (pt) * | 1989-11-17 | 1991-09-13 | Glaxo Group Ltd | Processo para a preparacao de derivados indole |
IE903911A1 (en) * | 1989-11-20 | 1991-05-22 | Ici Plc | Diazine derivatives |
GB8927277D0 (en) * | 1989-12-01 | 1990-01-31 | Glaxo Group Ltd | Chemical compounds |
EP0430709A3 (en) * | 1989-12-01 | 1992-02-12 | Glaxo Group Limited | Benzthiophen derivatives |
EP0430300A3 (en) * | 1989-12-01 | 1992-03-25 | Takeda Chemical Industries, Ltd. | Xanthine derivatives, their production and use |
US5104891A (en) * | 1989-12-11 | 1992-04-14 | G. D. Searle & Co. | Cycloheptimidazolone compounds as angiotensin ii antagonists for control of hypertension |
EP0434038A1 (fr) * | 1989-12-22 | 1991-06-26 | Takeda Chemical Industries, Ltd. | Dérivés condensés d'imidazole, leur préparation et leur utilisation |
NZ237476A (en) * | 1990-03-20 | 1994-01-26 | Sanofi Sa | N-substituted heterocyclic compounds and pharmaceutical compositions. |
WO1991015209A1 (fr) * | 1990-03-30 | 1991-10-17 | Merck & Co., Inc. | Pyrimidines, pyrimidinones et pyridopyrimidines substitues |
US5260325A (en) * | 1991-08-19 | 1993-11-09 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking tertiary amides |
-
1991
- 1991-02-12 EP EP91810098A patent/EP0443983B1/fr not_active Expired - Lifetime
- 1991-02-12 IL IL9721991A patent/IL97219A/en not_active IP Right Cessation
- 1991-02-12 PH PH41980A patent/PH30484A/en unknown
- 1991-02-12 DK DK91810098.3T patent/DK0443983T3/da not_active Application Discontinuation
- 1991-02-12 AT AT91810098T patent/ATE134624T1/de active
- 1991-02-12 ES ES91810098T patent/ES2084801T3/es not_active Expired - Lifetime
- 1991-02-12 DE DE1996175036 patent/DE19675036I2/de active Active
- 1991-02-12 DE DE122010000024C patent/DE122010000024I1/de active Pending
- 1991-02-12 DE DE200712000050 patent/DE122007000050I1/de active Pending
- 1991-02-12 DE DE59107440T patent/DE59107440D1/de not_active Expired - Lifetime
- 1991-02-15 NZ NZ237126A patent/NZ237126A/en unknown
- 1991-02-15 CA CA002232775A patent/CA2232775C/fr not_active Expired - Lifetime
- 1991-02-15 FI FI910747A patent/FI107921B/fi not_active IP Right Cessation
- 1991-02-15 CA CA002036427A patent/CA2036427C/fr not_active Expired - Lifetime
- 1991-02-18 NO NO910630A patent/NO304023B1/no not_active IP Right Cessation
- 1991-02-18 AU AU71151/91A patent/AU644844B2/en not_active Expired
- 1991-02-18 HU HU37/91A patent/HU219343B/hu unknown
- 1991-02-18 NO NO1999001C patent/NO1999001I2/no unknown
- 1991-02-18 HU HU9802895A patent/HU220073B/hu active Protection Beyond IP Right Term
- 1991-02-18 IE IE54891A patent/IE71155B1/en active Protection Beyond IP Right Term
- 1991-02-18 NO NO2007009C patent/NO2007009I2/no unknown
- 1991-02-18 PT PT96799A patent/PT96799B/pt active IP Right Grant
- 1991-02-19 JP JP3108097A patent/JP2749458B2/ja not_active Expired - Lifetime
- 1991-02-19 KR KR1019910002622A patent/KR0171409B1/ko not_active IP Right Cessation
-
1992
- 1992-12-29 US US07/998,755 patent/US5399578A/en not_active Expired - Lifetime
-
1993
- 1993-08-31 SA SA93140130A patent/SA93140130A/ar unknown
-
1994
- 1994-09-26 UY UY23835A patent/UY23835A1/es not_active IP Right Cessation
-
1996
- 1996-02-29 GR GR960400344T patent/GR3019155T3/el unknown
- 1996-07-18 LV LV960273A patent/LV5773B4/xx unknown
- 1996-12-24 HK HK219996A patent/HK219996A/xx not_active IP Right Cessation
-
1997
- 1997-01-04 NL NL970001C patent/NL970001I2/nl unknown
- 1997-07-16 LU LU90100C patent/LU90100I2/fr unknown
- 1997-09-05 CY CY197897A patent/CY1978A/xx unknown
-
1998
- 1998-04-06 FI FI980787A patent/FI980787A0/fi unknown
- 1998-07-29 US US09/124,520 patent/US5965592A/en not_active Expired - Fee Related
- 1998-10-21 NO NO1998024C patent/NO1998024I1/no unknown
- 1998-11-24 NL NL980036C patent/NL980036I2/nl unknown
-
1999
- 1999-03-09 LU LU90362C patent/LU90362I2/fr unknown
-
2007
- 2007-07-12 NL NL300285C patent/NL300285I1/nl unknown
- 2007-07-13 LU LU91347C patent/LU91347I2/fr unknown
-
2010
- 2010-04-07 LU LU91676C patent/LU91676I2/fr unknown
- 2010-04-14 NO NO2010008C patent/NO2010008I1/no unknown
- 2010-04-15 CY CY2010009C patent/CY2010009I2/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI107921B (fi) | Menetelmä terapeuttisesti käyttökelpoisten asyyliyhdisteiden valmistamiseksi | |
IE903749A1 (en) | Pyrimidines | |
EP0773932B1 (fr) | Derives de benzenesulfonamide comme antagonistes de la bradykinine | |
EP0719252B1 (fr) | Derives de 2-amino-1,2,3,4-tetrahydronaphtalene actifs au niveau de l'appareil cardio-vasculaire | |
US20080076760A1 (en) | 2,3,4,5-tetrahydro-1h-1,5-benzodiazepine derivative and medicinal composition | |
US7115777B2 (en) | Amide derivatives as inhibitors of the enzymatic activity of renin | |
RU2125990C1 (ru) | Производные замещенной гетероциклом фенил-циклогексан-карбоновой кислоты, смесь их изомеров или отдельные изомеры и их соли | |
CA2603030C (fr) | Derive de la benzyloxypropylamine | |
SK66793A3 (en) | Imidazolyl substituted derivatives of phenylpropane and cinnamon acid | |
WO1995013064A1 (fr) | Derives de l'acide 4-(1h-2-methylimidazo 4,5-c pyridinylmethyle)phenyle sulfonamide carboxylique en tant qu'antagonistes | |
JP4008446B2 (ja) | ベンゼン環上に二置換基を有するβ−ベンジルオキシアスパラギン酸誘導体 | |
US7018981B2 (en) | Cyclic motilin receptor antagonists | |
GB2096598A (en) | Novel amidine compounds | |
JPWO2003027060A1 (ja) | ジフェニルブタンアミド誘導体 | |
CN115340499B (zh) | Bcl-xl抑制剂及其用途 | |
JPS62223193A (ja) | β−遮断およびACE抑制化合物 | |
JPH0725854A (ja) | 縮合ベンゼンオキシ酢酸誘導体 | |
JPH08198820A (ja) | ジアダマンタン誘導体およびその用途 | |
JP2007513986A (ja) | 樹状トリメシン酸トリアミドの製法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or assigment of application |
Owner name: NOVARTIS AG |
|
SPCF | Supplementary protection certificate application filed |
Spc suppl protection certif: L20020008 Spc suppl protection certif: L20020009 |
|
SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: L201 Extension date: 20120124 Spc suppl protection certif: L200 Extension date: 20110512 |
|
SPCF | Supplementary protection certificate application filed |
Free format text: SPC L20070019 Spc suppl protection certif: L20070019 |
|
SPCG | Supplementary protection certificate granted |
Spc suppl protection certif: 238 Extension date: 20160215 |
|
SPCF | Supplementary protection certificate application filed |
Free format text: SPC C20100010 Spc suppl protection certif: C20100010 |
|
SPCP | Extension of a supplementary protection certificate [pediatric extension] |
Spc suppl protection certif: 200 Extension date: 20111112 |
|
SPCG | Supplementary protection certificate granted | ||
SPCR | Lapse or expiry of a supplementary protection certificate |
Spc suppl protection certif: L20020002 201 |
|
SPCR | Lapse or expiry of a supplementary protection certificate |
Spc suppl protection certif: 238 Spc suppl protection certif: 284 |